je.st
news
Tag: clinical analysis
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Root Cause Analysis for Clinical Research Professionals
2014-01-31 10:13:41| drugdiscoveryonline News Articles
Friday, March 21, 2014 1pm - 2:30pm EST 90 Minutes - Online $349 - Introductory Rate
Tags: research
analysis
professionals
clinical
Clinical Bioanalytical Analysis
2013-04-07 15:11:07| drugdiscoveryonline News Articles
Tags: analysis
clinical
bioanalytical
clinical analysis
Sites : [1]